Horizon Discovery

Company Website

About Horizon Discovery Group plc www.horizondiscovery.com Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines. Horizon offers over 23,000 catalogu.... Read more

Our online tool offers the flexibility to configure a synthetic or vector-based reag...

Further your functional genomics studies with CRISPR-Cas9 gene editing using Edit-R&...

Cell models to suit any application, from TIDVAL to antibody validation, delivered i...

Recapitulate disease phenotype Endogenous knock-in cell lines enable a clear und...

Choose from a range of popular cell line backgrounds, then simply deliver your CRISP...

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

Contact Horizon Discovery

Building 7300, Waterbeach
Cambridge,
CB25 9TL
United Kingdom
UK
+44 (0) 1223 976 000
Company Website